ArticleMetabolic brain disease2025
Tetrapleura tetraptera fruit extracts ameliorate pentylenetetrazol-induced seizures as well as ensuing cognitive deficit and oxidative stress.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kindling is an experimental-induced seizure consistent with epilepsy disease, a chronic neurological disorder characterised by spontaneous and repeated seizures. This disease is associated with oxidative stress, and most therapeutic strategies against epilepsy aim at improving the antioxidant defence mechanism in the brain. However, prolonged usage and associated adverse side effects limit antiepileptics, warranting natural antioxidant patronage. The present study investigated the behavioural and antioxidant actions of Tetrapleura tetraptera fruit extracts (TT) against pentylenetetrazol (PTZ)-kindling rats. Twenty-five male Wistar rats (150-180 g) were assigned into five groups (1-5, n = 5): Control (normal saline, 5 ml/kg body weight, b.w.), PTZ-only (40 mg/kg/b.w. i.p.), and groups 3-5 administered PTZ (40 mg/kg/b.w. i.p.) after, respectively, receiving oral TT (500 mg/kg/b.w.), TT flavonoid (fTT, 50 mg/kg/b.w.), and sodium valproate (SV, 15 mg/kg/b.w.). All administrations were carried out 48 hourly for 21 days. In the end, buried food, novel object recognition (NOR), Y-maze, elevated plus maze (EPM), and beam walk tests were done, and the rats were sacrificed. Whole brains were processed for antioxidant assays. The results showed a high (p <.05) seizure score and buried food test latency, preference for the familiar object in the NOR test, aversion to open-arm and reduced grooming in the EPM, reduced beam walk latency, elevated brain malondialdehyde (MDA), and decreased superoxide dismutase (SOD) in the PTZ group. The TT, fTT, and SV suppressed seizure, decreased buried food latency, `preference for the novel object and open-arm, increased grooming, decreased brain MDA, and elevated SOD. In conclusion, TT extracts protected against PTZ-induced cognitive deficits and brain oxidative stress, with results similar to those of the standard anticonvulsant drug, SV.
Indexed as
Identifiers
40072755What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.